证券日报网讯药石科技（300725）10月27日在互动平台回答投资者提问时表示，公司管理层始终密切关 注公司在资本市场的表现，并非常理解广大投资者对公司股价走势的关切。公司坚信，扎实的经营业绩 和持续的成长性是提升内在价值的根本保障，也是对股东最好的回报。目前，管理层正全力以赴聚焦主 营业务发展，通过持续提升经营管理水平、深化技术创新、优化客户与业务结构，不断夯实公司基本 面，以推动公司内在价值的持续增长。关于未来的具体增持计划或其他相关措施，如有安排，公司将严 格按照《深圳证券交易所创业板股票上市规则》等规定，及时履行信息披露义务。 ...

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

论坛聚焦绿色化学新理念、新技术与新应用，与会嘉宾通过交流分享，共同探索医药行业可持续发展路 径。"未来计划依托AI技术，进一步缩短研发周期、提升精准度，持续探索安全、环保、低碳的生产路 径。"论坛上，药石科技创始人、董事长兼首席执行官杨民民说。 论坛期间，技术分享环节、深度对话环节同步举行。 目前，南京生物医药谷集聚上下游生物医药类企业1300余家，已与南京大学、中国药科大学等共建南创 化学与生命健康研究院，不断推动合成生物、基因测序等前沿技术转化。(完) 中新网江苏新闻10月15日电(记者 葛勇)近日，第二届药石科技绿色化学论坛在南京江北新区举行。 本次论坛以"绿智未来 低碳向新"为主题，逾100位行业专家学者相聚在南京生物医药谷，探讨医疗行业 在全球供应链管理中的绿色变革。 论坛现场。苏正奇 摄 ...

Core Viewpoint - The stock of Yaoshi Technology has experienced fluctuations, with a recent decline of 2.01% and a year-to-date increase of 18.33%, indicating volatility in its market performance [1]. Financial Performance - As of September 30, Yaoshi Technology reported a revenue of 920 million yuan for the first half of 2025, reflecting a year-on-year growth of 23.48%. However, the net profit attributable to shareholders decreased by 26.54% to 72.5 million yuan [2]. - Cumulatively, since its A-share listing, Yaoshi Technology has distributed a total of 231 million yuan in dividends, with 137 million yuan distributed over the past three years [3]. Shareholder Information - The number of shareholders for Yaoshi Technology as of September 30 is 46,500, a decrease of 2.94% from the previous period. The average number of circulating shares per person increased by 3.03% to 4,363 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 2.1466 million shares, a decrease of 1.2259 million shares from the previous period, while Southern CSI 1000 ETF increased its holdings by 278,200 shares to 1.4751 million shares [3]. Business Overview - Yaoshi Technology, established on December 26, 2006, and listed on November 10, 2017, is primarily engaged in the research, development, production, and sales of drug molecular building blocks. Its revenue composition includes 83.14% from drug development and commercialization services, 16.72% from drug research services, and 0.14% from other sources [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and medical research outsourcing, and is involved in synthetic biology, biopharmaceuticals, innovative drugs, and cancer drugs [1].

（文章来源：证券日报） 证券日报网讯药石科技10月13日在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东人 数为：46457户。 ...

Core Viewpoint - The share reduction plan by Nanjing Novicos Venture Capital Partnership has been completed, resulting in a total cash inflow of 229 million yuan for the company [1]. Group 1: Share Reduction Details - Nanjing Novicos reduced 1,974,244 shares through centralized bidding at an average price of 46.21 yuan from August 11 to September 29, 2025 [2]. - Additionally, 3,430,500 shares were reduced through block trading at an average price of 40.18 yuan from August 13 to September 26, 2025 [2]. - The total shares reduced by Nanjing Novicos amounted to 5,404,744 shares [1][2]. Group 2: Shareholder Information - The controlling shareholder and actual controller of the company is Yang Minmin, who is also the executive partner of Nanjing Novicos [3]. - Nanjing Novicos is considered a concerted actor with Yang Minmin, indicating a close relationship in decision-making [3].

Core Viewpoint - The employee shareholding platform of Yaoshi Technology, Novicos, has completed its share reduction plan, selling a total of 5.404744 million shares, which accounts for 2.32% of the total share capital after excluding repurchased shares [1] Summary by Category Share Reduction Details - Novicos reduced its holdings from August 11, 2025, to September 29, 2025, through centralized bidding and block trading [1] - The centralized bidding resulted in a reduction of 1.974244 million shares at an average price of 46.21 CNY per share [1] - The block trading led to a reduction of 3.430500 million shares at an average price of 40.18 CNY per share [1] - The total estimated amount from the share reduction is approximately 229 million CNY [1] - After this reduction, Novicos no longer holds any shares in Yaoshi Technology [1]

证券代码：300725 证券简称：药石科技 公告编号：2025-096 南京药石科技股份有限公司 关于股东减持股份计划实施完成的公告 股东南京诺维科思创业投资合伙企业（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 南京药石科技股份有限公司（以下简称"公司"）于2025年7月10日披露了 《关于公司股东减持股份的预披露公告》（公告编号：2025-044）。公司员工持 股平台南京诺维科思创业投资合伙企业（有限合伙）（以下简称"诺维科思"） 计划在本减持计划预披露公告之日起十五个交易日后的三个月内（窗口期不减 持），以集中竞价、大宗交易方式减持其持有的全部公司股份。其中，通过集中 竞价交易方式减持的，在任意连续90个自然日内减持股份数量不超过公司股份总 数的1.00%；通过大宗交易方式减持的，在任意连续90个自然日内减持股份数量 不超过公司股份总数的2.00%（减持期间如公司有送股、资本公积金转增股本等 导致持股数量变化，则减持数量进行相应调整）。 2025年9月29日，公司收到了诺维科思出具的《关于 ...

Group 1 - The company, Yaoshi Technology, positions itself as a global chemical technology innovation platform in the pharmaceutical R&D and manufacturing sector [1] - The company leverages its advantages in molecular building block design and synthesis technology, as well as green low-carbon chemical technology, to explore applications across multiple fields [1] - The company aims to extend its technological capabilities from chemical drugs to new materials, new energy, and green agriculture, thereby building a cross-industry technology empowerment system [1] Group 2 - The company commits to timely information disclosure in accordance with legal regulations if there are significant business developments that meet disclosure standards [1]

Core Viewpoint - The company is focusing on the development opportunities in the oligonucleotide drug field and has established a specialized team to enhance its capabilities in this area [1] Group 1 - The company has designed a diverse range of molecular building blocks, including nucleotides, phosphoramidites, and delivery technologies, with over 500 product types currently available [1] - In the first half of this year, the company integrated internal resources to establish a professional peptide and oligonucleotide team (PTCoE) [1] - The company is accelerating its capabilities in oligonucleotide synthesis, chemical modification, conjugation, process development, and analysis [1] Group 2 - The company will continue to closely monitor industry technology development trends and will timely advance relevant layouts [1]